

## EXECUTIVE SUMMARY

# 019 Specialty Dental Brands Transaction Review

The [Health Care Market Oversight](#) (HCMO) program reviews proposed health care business deals to make sure they do not harm people and communities in Oregon. After completing a review, the Oregon Health Authority (OHA) issues a decision about whether a business deal, or transaction, involving a health care company should proceed.

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact us by email at [hcmo.info@oha.oregon.gov](mailto:hcmo.info@oha.oregon.gov) or by phone at 503-385-5948. We accept all relay calls.

## Proposed Transaction

On February 1, 2024, OHA accepted a completed [notice of material change transaction](#) describing plans to restructure the ownership and debt of Specialty Dental Brands (SDB).

## OHA's Review

OHA completed a preliminary review of the proposed transaction. During the review, OHA assessed the likely impact of the transaction across four domains: cost, access, quality, and equity. OHA held a public comment period and received no public comment submissions.

## Key Findings



### Cost

The proposed transaction is unlikely to affect costs because no consolidation is occurring. The change in ownership is unlikely to affect prices for services.



### Access

The Oregon locations will continue to provide the same types of services to patients in the same geographic region. The proposed transaction is also unlikely to impact the types of payments that OR Specialty Dental accepts.



### Quality

The transaction is unlikely to affect health care quality. OR Specialty Dental will continue to provide the same types and amounts of medical services to individuals in the same geographic regions.



### Equity

The proposed transaction is unlikely to affect the types of services offered at locations in Oregon, the staff who treat patients, or the patients' ability to access services. The restructuring is unlikely to affect health equity.

## Conclusions and Decision

OHA [approved the transaction](#) on March 11, 2024.

OHA will monitor the impact of the transaction by conducting follow up analyses one year, two years, and five years after the business deal is completed. During these reviews, OHA will analyze

March 11, 2024

## EXECUTIVE SUMMARY

any impact of the transaction on quality of care, access to care, affordability, and health equity, specifically following up on concerns or observations noted in the Findings & Potential Impacts section of the Review Summary Report. OHA will also assess whether the parties to the transaction have kept to the commitments stated in the notice of transaction regarding cost, access, and quality of care.